BioMedNewsBreaks Archive - Page 35 of 175

FridayAug 04, 2023 11:10 am

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Delays SRM Entertainment Inc. Spin-Off, Distribution of Common Stock

Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair metabolism and skin therapies, has temporarily postponed the spin-off and common stock distribution of its majority-owned subsidiary, SRM Entertainment Inc. According to the announcement, the distribution of shares of common stock at $0.0001 per share has been delayed; the distribution had been planned for Aug. 3, 2023, with the trading date of SRM common stock on the NASDAQ exchange beginning on Aug. 4, 2023. The announcement did note that the previously announced record date of July 7, 2023, remains the same. “The company remains intent on effectuating the distribution as soon…

ThursdayAug 03, 2023 12:47 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports on Berubicin Pivotal Study, Announces Participation in Biotech Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, released an update on its ongoing clinical study evaluating Berubicin for the treatment of recurrent GBM, an aggressive and incurable form of brain cancer. According to the report, the company continues to see rapid progression and acceleration of enrollment for the study, with 180 patients of the 243 expected currently enrolled across 46 clinical trial sites. In addition, CNS has documented the necessary number of patients reaching the primary efficacy endpoint, or overall survival, to conduct…

ThursdayAug 03, 2023 11:20 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) UNBUZZD Definitive Agreement Featured by Investment Pitch Media

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, is spotlighted on the latest InvestmentPitch Media release. The media release discusses FSD Pharma’s recently executed definitive agreement that grants exclusive rights to Celly Nutrition for recreational applications of its alcohol misuse technology and the launch of UNBUZZD(TM), a revolutionary rapid alcohol detoxification drink. According to the agreement, Celly Nu will pay FSD a license fee by issuing 100,000,000 shares and a 7% royalty on gross revenue if…

WednesdayAug 02, 2023 1:02 pm

BioMedNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Expands Phase 2 Trial to Add New Site

IGC Pharma (NYSE American: IGC) today announced the addition of an important trial site at the University of Puerto Rico network as an expansion of its ongoing phase 2 clinical trial investigating lead drug asset, IGC-AD1, as a treatment for lowering agitation in patients with Alzheimer’s disease. According to clinicaltrials.gov, IGC-AD1 is the only natural THC-based investigational drug undergoing FDA trials. The therapy relies on low doses of THC and another compound as pharmaceutical active agents for the treatment of Alzheimer’s and, in pre-clinical and phase 1 studies, has shown the potential to be effective in ameliorating Aβ plaques and…

WednesdayAug 02, 2023 12:54 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement to Launch UNBUZZD

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders. The company today announced its entry into a definitive agreement with Celly Nutrition Inc. to grant exclusive rights to recreational applications for FSD Pharma’s alcohol misuse technology and launch UNBUZZD. A revolutionary, rapid alcohol detoxification drink, UNBUZZD was created by scientists and the expert clinical research team at FSD Pharma. “This is a major milestone for our company,” said Zeeshan Saeed, founder, CEO and executive co-chairman of the…

WednesdayAug 02, 2023 12:44 pm

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Releases Anticipated Payment Date for SRM Entertainment Common Stock Distribution

Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair metabolism and skin therapies, is reporting the payment date for the distribution of shares of common stock, par value $0.0001 per share, of SRM Entertainment Inc. The announcement noted that the payment date remains subject to SRM’s amended registration statement on form S-1 along with the approval of the listing of the SRM common stock on NASDAQ and obtaining certain other approvals in connection with the offering. SRM is currently a majority-owned subsidiary of Jupiter Wellness, which is expected to spin-off tomorrow. “In the event that such registration statement is…

WednesdayAug 02, 2023 10:52 am

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Granted Extension to Regain NASDAQ Compliance

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, received an extension from NASDAQ to regain compliance with listing rules. The extension, which is good until Oct. 30, 2023, was granted after NASDAQ reviewed BiondVax’s detailed plan to regain compliance. BiondVax submitted the plan after receiving a May 1, 2023, deficiency letter from NASDAQ. “We are very pleased that NASDAQ has reviewed our plan and provided us the time to proceed with various initiatives already underway that alone or together will allow us to…

TuesdayAug 01, 2023 12:26 pm

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Names New Advisory Board Member

Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair metabolism and skin therapies, has announced a new member of its advisory board. David Long, cofounder and CEO of Orangetheory Fitness, has joined JUPW’s board to support the company’s launch of its newest product: Safety Shot. Long previously served on GBB Drink Lab’s advisory board, playing a key role in guiding the development and marketing of the world’s first rapid alcohol detox drink, which was recently acquired by JUPW. Long brings an impressive resume to his new board appointment. He oversaw the growth of Orangetheory Fitness to include the opening of…

TuesdayAug 01, 2023 10:53 am

BioMedNewsBreaks – Ocean Biomedical Inc. (NASDAQ: OCEA) Shares Promising Results on World Lung Cancer Day

On World Lung Cancer Day, Ocean Biomedical (NASDAQ: OCEA) shared details of its multipronged lung cancer program built on novel immunotherapy discoveries by Scientific Co-founder Dr. Jack A. Elias. According to the announcement, Dr. Elias and his team have revealed that Chitinase 3-like-1 (“CHi3L1”) is a master regulator that inhibits antitumor immune responses. Ocean Biomedical’s lung cancer program is advancing several approaches to reversing immune system suppression caused by CHi3L1 alone and in combination with other immunotherapy pathways. The programs suppress primary and metastatic tumor growth in numerous animal models and hold potential use in multiple forms of visceral cancers.…

FridayJul 28, 2023 12:41 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leveraging Unique NanoAb Pipeline to Target Large, Growing Markets

BiondVax (NASDAQ: BVXV) is an innovative biotechnology company focused on developing, manufacturing and commercializing potential blockbuster immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company is developing a pipeline of unique nanosized antibody (“NanoAb”) therapies addressing diseases underserved by current treatments with large, growing markets, including dermatological conditions such as psoriasis. “BiondVax is initially targeting IL-17 [the human immune system cytokine, which is implicated in several diseases] for the treatment of psoriasis, where the market for therapeutics is expected to reach $44 billion by 2031,” reads a recent article. “The company’s plan for the IL-17 nanobody…

News and publishing service for medical and biotechnology related companies

Contact us: 415.949.5050

BioMedNewsBreaks

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Delays SRM Entertainment Inc. Spin-Off, Distribution of Common Stock

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports on Berubicin Pivotal Study, Announces Participation in Biotech Conference

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) UNBUZZD Definitive Agreement Featured by Investment Pitch Media

BioMedNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Expands Phase 2 Trial to Add New Site

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement to Launch UNBUZZD

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Releases Anticipated Payment Date for SRM Entertainment Common Stock Distribution

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Granted Extension to Regain NASDAQ Compliance

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Names New Advisory Board Member

BioMedNewsBreaks – Ocean Biomedical Inc. (NASDAQ: OCEA) Shares Promising Results on World Lung Cancer Day

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leveraging Unique NanoAb Pipeline to Target Large, Growing Markets

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search